---
title: "Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293364061.md"
description: "Cellectar BioSciences plans to seek US accelerated approval for iopofosine I-131 in Waldenström macroglobulinemia by late 2027 or early 2028. A Phase 3 confirmatory trial is planned with first patient enrollment in Q1 2027, targeting a cost of USD 42 million. Previous Phase 2b data showed strong efficacy, including an 83.6% overall response rate and median progression-free survival of 406 days."
datetime: "2026-07-21T15:41:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293364061.md)
  - [en](https://longbridge.com/en/news/293364061.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293364061.md)
generator: "portal-rs"
---

# Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia

-   Cellectar BioSciences outlined plans to seek US accelerated approval for iopofosine I 131 in Waldenström macroglobulinemia in 1H27. \* Phase 3 confirmatory trial planned with first patient enrollment projected for 1Q27; potential approval targeted for 4Q27 or 1Q28. \* Phase 2b CLOVER-WaM data showed major response rate 61.8%, overall response rate 83.6%, disease control rate 98.2% in 55 evaluable patients. \* Median duration of response 533 days; median progression-free survival 406 days, based on a Dec 2025 data cutoff. \* Phase 3 design targets 200 patients; estimated total study cost USD 42 million, including about USD 15 million to accelerated approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md)

## Related News & Research

- [Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate oncology platform, iopofosine I-131 program](https://longbridge.com/en/news/296262041.md)
- [Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/296502875.md)
- [Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | CLRB Stock News](https://longbridge.com/en/news/295789747.md)
- [Cellectar Biosciences Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/295806334.md)
- [CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials](https://longbridge.com/en/news/296262059.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**